Sapphire Star Partners Lp Lowers stake in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Sapphire Star Partners Lp reduced its stake in Eli Lilly and Co by 45.67% during the most recent quarter end. The investment management company now holds a total of 18,374 shares of Eli Lilly and Co which is valued at $1,473,962 after selling 15,448 shares in Eli Lilly and Co , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Eli Lilly and Co makes up approximately 1.67% of Sapphire Star Partners Lp’s portfolio.

Other Hedge Funds, Including , Guardian Capital Advisors Lp reduced its stake in LLY by selling 200 shares or 3.17% in the most recent quarter. The Hedge Fund company now holds 6,100 shares of LLY which is valued at $489,342. Eli Lilly and Co makes up approx 0.09% of Guardian Capital Advisors Lp’s portfolio.B T Capital Management Dba Alpha Capital Management reduced its stake in LLY by selling 12,533 shares or 28.5% in the most recent quarter. The Hedge Fund company now holds 31,443 shares of LLY which is valued at $2,522,357. Eli Lilly and Co makes up approx 1.75% of B T Capital Management Dba Alpha Capital Management’s portfolio. Hikari Power Ltd added LLY to its portfolio by purchasing 8,500 company shares during the most recent quarter which is valued at $703,120. Eli Lilly and Co makes up approx 0.08% of Hikari Power Ltd’s portfolio.Glynn Capital Management reduced its stake in LLY by selling 2,000 shares or 20.24% in the most recent quarter. The Hedge Fund company now holds 7,880 shares of LLY which is valued at $653,173. Eli Lilly and Co makes up approx 0.19% of Glynn Capital Management’s portfolio.Legacy Private Trust reduced its stake in LLY by selling 3,220 shares or 26.65% in the most recent quarter. The Hedge Fund company now holds 8,862 shares of LLY which is valued at $708,517. Eli Lilly and Co makes up approx 0.10% of Legacy Private Trust’s portfolio.

Eli Lilly and Co opened for trading at $78.33 and hit $78.74 on the upside on Monday, eventually ending the session at $78.6, with a gain of 0.46% or 0.36 points. The heightened volatility saw the trading volume jump to 22,03,303 shares. Company has a market cap of $86,762 M.

On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Leave a Reply

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.